XERS

Xeris Biopharma Holdings Stock Analysis

AI Rating

Good
  • Quality7/10
  • Growth↑ 8/10
  • Momentum↑ 6/10
Xeris Biopharma Holdings sales and earnings growth
XERS Growth
Good
  • Revenue Y/Y↑ 42.05%
  • EPS Y/Y↑ 77.27%
  • FCF Y/Y↑ 130.92%
Xeris Biopharma Holdings gross and profit margin trends
XERS Profitability
Neutral
  • Gross margin ↑ 84.60%
  • EPS margin↓ -5.90%
  • ROIC↓ 4.50%
Xeris Biopharma Holdings net debt vs free cash flow
XERS Risk
Great
  • Debt / Equity↓ -299.2
  • Debt / FCF↑ 16.6
  • Interest coverage↓ 0.5

Xeris Biopharma Holdings stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗